Ceftobiprole

From IDWiki

Background

Mechanism of Action

Spectrum of Activity

  • Active against MRSA, ampicillin-susceptible Enterococcus, and penicillin-resistant Streptococcus pneumoniae, as well as aerobic Gram-negative bacteria similar to other third-generation cephalosporins
  • Not active against Pseudomonas, ESBL-producers, or AmpC-producers

Pharmacokinetics and Pharmacodynamics

  • Crosses into CSF adequately

Dosing

  • Ceftobiprole 500 mg IV q8h over 2 hours

Renal Dosing

  • Required if CrCl <50 mL/min

Safety

Adverse Drug Reactions

  • Nausea, diarrhea, neutropenia (4%), dysgeusia